shrinking pipeline

Quote






Because they didn't want to throw good money after bad. MRL has been a failure for many years. It's living proof that you can't just throw money at the problem and find solutions.

Merck, like it's pipeline, is drying up.
 












Everything is shrinking. Enthusiasm, talent pool, opportunities. If any scientist were still foolish enough to enter this industry, why would they bet their efforts on certain mediocrity at a company like Merck versus taking a chance at starting their career at a smaller, more energetic place. A place where they would see how much difference they can make and yet grow professionally at the same. At Merck, there are now so many people getting free rides from others hard work that having it otherwise seems strange. Management is no longer even taking any measures to make it seem otherwise - they seem to put all their efforts into making it worse. Could it be that this place is run by a modern-day Louis XVI and Marie Antoinette. Wouldn't you rather take a chance on a so-so product making it at a company where the employees have a sense of urgency than betting on a so-so product surviving at Merck where that sense of doom is the furthest thing from anyone's mind. Merck already knows how remote the chances of making things work are and they now believe that dumping candidates early is preferable to fixing the environment so those so-so candidates might be better bets. The number of companies out there with R&D budgets that are a fraction of Merck's and who are more than glad to move so-so products forward is surprising. And they are the future of pharma, not Merck and its mega-clones.
 






Merck has tried to buy its way out of this mess, but to no avail. The only bonafide products that we have left are Singulair, Januvia and Gardisil---and all of them were developed elsewhere. Gardisil's growth is finished. Singulair disappears soon. Januvia is about to get a whole lot of competition; it's Lipitor is just around the corner. The pipeline is an empty cavern; collectively, every likely candidate won't replace even Singulair alone. This company is finished.
 






Anonymous said:
Merck has tried to buy its way out of this mess, but to no avail. The only bonafide products that we have left are Singulair, Januvia and Gardisil---and all of them were developed elsewhere. Gardisil's growth is finished. Singulair disappears soon. Januvia is about to get a whole lot of competition; it's Lipitor is just around the corner. The pipeline is an empty cavern; collectively, every likely candidate won't replace even Singulair alone. This company is finished.
Click to expand...

The company can survive and even do well if it's willing to thrash the whole research leadership, Peter Kim and all his cronies, into the dustbin of history, and reorganize. The only thing these guys do is shuffling and reshuffling slick Power Point slide decks to impress and deceive the executive committee and BOD. They have no respect for the excellence in science that drives the discovery process. They should all be demoted and made to work on the bench, or thrown out of the companies. They remind me of the despots of the Middle East. Enough is enough, the thieves must leave.
 












Top Bottom
Back
Quote